linjc16/ctgov huggingface dataset:
Exercise Intervention for Patients With Sarcopenia or Frailty in Long-term Care Institutions

Study Overview
=================
Brief Summary
-----------------
Sarcopenia is a geriatric syndrome of decreased muscle volume with muscular function decline. There is more tendency for sarcopenic elderly to be frail, disabled, or have cardiovascular disease. Compared to those who are not sarcopenic, they also had worse prognosis in response to treatment for definite diseases, and spend more medical cost. Exercise appears to have an important role in management of sarcopenia. In the current study, the investigators provide an exercise program, including resistance/balance training for the elderly with sarcopenia or frailty in long-term care institution, and evaluate the effect.

Official Title
-----------------
Exercise Intervention for Patients With Sarcopenia or Frailty in Long-term Care Institutions

Conditions
-----------------
Sarcopenia

Intervention / Treatment
-----------------
* Behavioral: Group exercise program
* Behavioral: Self exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >20-year-old diagnosed with sarcopenia (by the definition from Asia workgroup for sarcopenia, AWGS) or frailty (The Fried model, based on five functional criteria) Exclusion Criteria: Severe medical diseases or mental problems, which result in difficulty to follow exercise program. Inability to get down from bed for activity due to disease, such as neuropathy or orthopedic disease. High risk group for exercise program, such as those with unstable fracture or nonunion fracture. Anyone who didn't want attend this study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group exercise program by coach<br> | Behavioral: Group exercise program<br>* Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions. Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks.<br>|
| Sham Comparator: Self exercise<br> | Behavioral: Self exercise program<br>* Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength | grasp strength by dynamometer | after 16-weeks training | 
| walk speed | 6-meter walk test | after 16-weeks training |
Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients

Study Overview
=================
Brief Summary
-----------------
Most of the real world evidence data related to efficacy of cysteamine therapy is retrospective. This study is a ambispective study to investigate the impact of cystine depletion therapy on the quality of life of patients and their parents.

Official Title
-----------------
Multicentre, Ambispective, Observational, Real Life Study to Assess the Quality of Life Effectiveness of Extended Release (ER) Oral Cysteamine Therapy (Procysbi) in Belgian Patients Suffering From Nephropathic Cystinosis

Conditions
-----------------
Nephropathic Cystinosis

Intervention / Treatment
-----------------
* Drug: Cysteamine Bitartrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Confirmed diagnosis of nephropathic cystinosis Undergoing cystine depletion therapy with oral cysteamine Signature of informed concent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Patients on extended release cysteamine treatment at study enrollment | Drug: Cysteamine Bitartrate<br>* ERT<br>|
| Cohort 2<br>Patients switching from immediate release cysteamine to extended release cysteamine during the study | Drug: Cysteamine Bitartrate<br>* ERT<br>|
| Cohort 3<br>Patients remaining on immediate release cysteamine treatment | Drug: Cysteamine Bitartrate<br>* ERT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to descriptively assess the change from baseline and percent change from baseline in the quality of life overall summary sores at 12 months in switch cohort |  | 12 months |
MitraClip for Severe TR

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate the procedural feasibility and 30-day results of transcatheter tricuspid valve repair using the MitraClip® system (Abbott Vascular) in selected, highly symptomatic patients with severe tricuspid regurgitation (TR).

Detailed Description
-----------------
The primary objectives of this prospective analysis were to determine the feasibility in terms of success rate and short-term clinical follow-up at 30 days. In this context procedural success was defined as reduction of at least one TR grade. At 30-days after the procedure, a clinical follow up was performed in the heart failure outpatient clinic of our department including transthoracic echocardiography for the evaluation of TR grades. Furthermore, the investigators determined NYHA functional class and the incidence of major adverse cardiac and cerebrovascular events (MACCE). Secondary objectives were the assessment of right ventricular function, the 6-minute walk distance, NT-proBNP as well as quality of life as assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) score at 30-days follow up.

Official Title
-----------------
Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System

Conditions
-----------------
Tricuspid Regurgitation

Intervention / Treatment
-----------------
* Device: MitraClip in tricuspid valve


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: right-sided heart failure due to moderate-to-severe tricuspid regurgitation patients deemed inoperable by the heart Team Exclusion Criteria: poor Echo-image quality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MitraClip in tricuspid valve|MitraClip in tricuspid valve|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TR grade, Echo (grade 0-4) | grade 0-4: 0: no tricuspid regurgitation, 4: massive TR | 1-12 months | 
| MACCE |  | 1-12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NYHA status |  | 1-12 months | 
| 6 Minute walk distance |  | 1-12 months | 
| NT-proBNP |  | 1-12 months | 
| MLHFQ |  | 1-12 months |
Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.

Official Title
-----------------
Effects of Combined Sevoflurane and Nitrous Oxide Inhalation

Conditions
-----------------
Opioid-Related Disorders, Substance-Related Disorders

Intervention / Treatment
-----------------
* Drug: 30% Nitrous oxide
* Drug: 0.4% Sevoflurane
* Drug: 0.2% sevoflurane
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo +/- 30% Nitrous oxide<br> | Drug: 30% Nitrous oxide<br> <br> Other: Placebo<br> <br> |
| Active Comparator: Sevoflurane 0.2% +/- 30% Nitrous oxide<br> | Drug: 30% Nitrous oxide<br> <br> Drug: 0.2% sevoflurane<br> <br> |
| Active Comparator: Sevoflurane 0.4% +/- 30% Nitrous oxide<br> | Drug: 30% Nitrous oxide<br> <br> Drug: 0.4% Sevoflurane<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity, pain bothersomeness | Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4 | During inhalation | 
| Mood | Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4 | During inhalation | 
| Psychomotor performance | Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4 | During inhalation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitrous oxide, sevoflurane, drug interaction, subjective effects, analgesia, healthy volunteers
Dietary Interventions for Muscle Mass

Study Overview
=================
Brief Summary
-----------------
Dietary intervention to prevent sarcopenia in elderly people. The objective of this study is to test whether meat structure plays an important role in protein digestion, to maximise the amino acid availability and to stimulate the muscle protein growth in elderly people.

Official Title
-----------------
Dietary Interventions for Muscle Mass

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Other: Intact or minced beef meat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-obese male subjects (BMI<30) between the age of 65-85 years. Exclusion Criteria: Type II diabetes or other known diseases, use of medication, female, other ages or BMI than indicated above, participation in any regular exercise program.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Beef steak<br> | Other: Intact or minced beef meat<br>* 135 gram piece of intact or minced beef meat, beef steak or minced beef resp.<br>* Other names: Ground beef;|
| Experimental: Minced beef<br> | Other: Intact or minced beef meat<br>* 135 gram piece of intact or minced beef meat, beef steak or minced beef resp.<br>* Other names: Ground beef;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle protein synthesis | Muscle protein synthesis will be expressed as fractional synthetic rate (FSR) by dividing the increment in enrichment in the product, i.e. protein-bound D5phe tracer, by the enrichment of the precursor (=plasma availability). | 6 h postprandial period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dietary amino acid plasma availability | The exogenous rate of phenylalanine appearance will be used to assess the bio-availability of dietary-protein derived amino acids in the circulation during the 6h postprandial period following meat intake | 6h postprandial period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
muscle, FSR, protein, meat
Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection

Study Overview
=================
Brief Summary
-----------------
Human papillomavirus (HPV) infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection. In this study the investigators will evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improve the viral clearance reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available. Women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynaecological solution (Monogin®) or to remain untreated for the same period of time. The administration of Monogin® has been performed every three days for fifteen days and then every fifteen days for the subsequent six months.

Conditions
-----------------
HPV Infection

Intervention / Treatment
-----------------
* Device: Monogin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pathologic Pap smear positive high risk HPV DNA test positive colposcopy examination Exclusion Criteria: patients who had undergone wart therapy in the previous six months pregnancy invasive disease immunosuppression previous HPV vaccination

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Monogin<br> | Device: Monogin<br>* Gynaecological solution with polyhexamethylene biguanide, pH 4.0<br>|
| No Intervention: No intervention<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with no HPV infection |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, polyhexamethylene biguanide, intraepithelial lesions, regression rate
Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

Study Overview
=================
Brief Summary
-----------------
This study is being done to evaluate the effect of targeted UV-B (a component of sunlight) on the treatment of acne keloidalis nuchae (AKN, or razor bumps on the back of the neck). The investigators believe targeted UV-B is a safe and effective way to reduce the appearance of AKN.

Official Title
-----------------
Improving Acne Keloidalis Nuchae by Inducing Matrix Metalloproteinases in Vivo Using Targeted Ultraviolet-B Irradiation

Conditions
-----------------
Acne Keloidalis Nuchae

Intervention / Treatment
-----------------
* Radiation: Targeted UV-B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 or over male gender African-American or other black ethnicity current diagnosis of acne keloidalis nuchae (razor bumps on back of neck) Exclusion Criteria: allergy to lidocaine or numbing medicine history of increased sensitivity to sunlight, lupus, or porphyria current use of a drug that increases sensitivity to sunlight

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Targeted UV-B (Left)<br>Targeted UV-B on left side of the scalp. | Radiation: Targeted UV-B<br>* Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)<br>|
| Experimental: Targeted UV-B (Right)<br>Targeted UV-B on right side of the scalp. | Radiation: Targeted UV-B<br>* Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage Change in Total AKN Lesions From Baseline to Week 16. | To determine if treatment of AKN with targeted ultraviolet B radiation will improve the clinical appearance of lesions. | Baseline to Week 16 |
Stereotactic Radiation to Decrease Pancreatic Secretions

Study Overview
=================
Brief Summary
-----------------
Patients that have undergone pre-operative radiation for pancreatic carcinoma, that upon pathologic examination of the normal portion of the pancreatic gland that was in the radiation field showed acute and chronic changes in the pancreatic cells. The hypothesis for utilizing stereotactic radiation on pancreatic fistulae is that the treatment will decrease pancreatic secretions, thus decreasing autodigestion.

Detailed Description
-----------------
Stereotactic radiation for cancer has been utilized to successfully treat the head of the pancreas, which is generally a well-tolerated procedure with minimal complications. Upon further investigation under the microscope, after resection during a complex Whipple operation, it is noted that particularly the exocrine glandular tissue atrophied substantially. Based on this information, the hypothesis for utilizing stereotactic radiation on the remaining pancreas is production of a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland. The use of stereotactic radiation will be performed on individuals that are non-surgical candidates.

Official Title
-----------------
Utilization of Stereotactic Radiation in Patients With Pancreatic Fistula to Decrease Pancreatic Secretions

Conditions
-----------------
Pancreatic Fistulae

Intervention / Treatment
-----------------
* Radiation: Stereotactic Radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pancreatic fistula Non-surgical candidate Exclusion Criteria: Surgical candidate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stereotactic Radiation<br>Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery. | Radiation: Stereotactic Radiation<br>* Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decreased Secretions | Measurement of pancreatic panel, decreased Pancreatic Secretions | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreas, Pancreatic fistula, Stereotactic radiation
Vitamin D for Improving Metabolic Control and Depressive Symptoms

Study Overview
=================
Brief Summary
-----------------
This study will examine whether weekly vitamin D supplementation in women with significant depressive symptoms and diabetes will exhibit improved mood and metabolic control. If supplementation with Vitamin D is beneficial, it will be a simple and cost-effective method for treatment. Women will be targeted since they have greater depression and worse metabolic control than men with diabetes.

Official Title
-----------------
Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study

Conditions
-----------------
Depressive Symptoms, Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin D supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 18 and older medically stable type 2 diabetes with HBA1c <9%. significantly elevated depressive symptoms as measured by a score greater than or equal to 14 using the Center for Epidemiologic Studies Depression Tool (CES-D. Exclusion Criteria: vitamin D levels of 32 ng/dl or greater malabsorption problems (e.g., crohn's disease, celiac sprue) hypercalcemia-level greater than 10.5 mg/dl Severe complications of diabetes (amputation, blindness, or renal problems) 5) Women with low thyroid function 6) active suicidal ideation, a history of bipolar depression, psychotic disorders, and current alcohol or substance disorders. Active treatment for depression (e.g., antidepressant therapy) will not be exclusion criteria 7) Any serious chronic illness that may impact on their health-related quality of life and treatment effect 8) Women who are pregnant 9) Women who have had bariatric surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D supplementation<br>The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months. | Dietary Supplement: Vitamin D supplementation<br>* Vitamin D2 50,000 IU will be administered once a week for six months.<br>* Other names: Drisdol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic control |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| depressive symptoms |  | 6 months |